Market Place
News Type
Setting a smart pace for the extended Topicals Rx marketplace. 
X
Details:
Zomig® Nasal Spray is distributed in a unique unit dose presentation and is indicated for the treatment of migraine headaches with or without aura in adults and pediatric patients (12 to 17 years of age).
Lead Product(s): Zolmitriptan
Therapeutic Area: Neurology Product Name: Zomig
Highest Development Status: Approved Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 16, 2021
DDF Summit 2022 US
Not Confirmed
Contact SupplierDetails:
AJOVY (fremanezumab) has been shown to be an effective migraine preventive treatment in a range of patients including those with depression and anxiety.
Lead Product(s): Fremanezumab-vfrm
Therapeutic Area: Neurology Product Name: Ajovy
Highest Development Status: Approved Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 08, 2022
Details:
Midazolam 10 mg autoinjector is indicated for the treatment of status epilepticus, or prolonged seizures, in adults. According to U.S. JPEO-CBRND, the autoinjector improves upon and will replace the currently fielded convulsant antidote for nerve agent diazepam autoinjector.
Lead Product(s): Midazolam
Therapeutic Area: Neurology Product Name: Undisclosed
Highest Development Status: Approved Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 30, 2022
Details:
The real-world effectiveness of Ajovy (fremanezumab) in patients with refractory migraine from a US tertiary headache center who switched from erenumab study was also highlighted.
Lead Product(s): Fremanezumab
Therapeutic Area: Neurology Product Name: Ajovy
Highest Development Status: Approved Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 09, 2022
Details:
AJOVY (fremanezumab) is indicated for the preventive treatment of migraine in adults who have at least four migraine days per month, is a subcutaneous injection for the preventive treatment of migraine in adults who have at least four migraine days per month.
Lead Product(s): Fremanezumab
Therapeutic Area: Neurology Product Name: Ajovy
Highest Development Status: Approved Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 17, 2022
Details:
Real-world data will be presented regarding reductions in acute medication use for migraine patients initiating Ajovy, a calcitonin gene-related peptide antagonist, as well as a study evaluating healthcare resource use of patients initiating Ajovy.
Lead Product(s): Fremanezumab
Therapeutic Area: Neurology Product Name: Ajovy
Highest Development Status: Approved Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 01, 2022
Details:
GA Depot is a long-acting injection version of the approved Copaxone® (Glatiramer Acetate) designed to be administered as an intramuscular injection once every four weeks, is being evaluated for treatment of relapsing forms of multiple sclerosis.
Lead Product(s): Glatiramer Acetate
Therapeutic Area: Neurology Product Name: Copaxone
Highest Development Status: Approved Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 30, 2022
Details:
Patients were eligible for the study if they were diagnosed with relapsing MS (RMS), gave a live birth, were breastfeeding under GA treatment (COPAXONE® 20 or 40 mg/mL) or breastfeeding under no DMT treatment.
Lead Product(s): Glatiramer Acetate
Therapeutic Area: Neurology Product Name: Copaxone
Highest Development Status: Approved Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 13, 2021
Details:
Extension analyses observed patients taking AJOVY experienced a reduction in migraine and headache days and evaluated disability and health-related quality of life.
Lead Product(s): Fremanezumab
Therapeutic Area: Neurology Product Name: Ajovy
Highest Development Status: Approved Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 30, 2021
Details:
AJOVY is the first long-acting (defined as efficacy measured over a 12-week period following a 675 mg [225 mg x 3] subcutaneous dose) anti-CGRP subcutaneous injection approved for the preventive treatment of migraine in adults with both quarterly and monthly dosing options.
Lead Product(s): Fremanezumab
Therapeutic Area: Neurology Product Name: Ajovy
Highest Development Status: Approved Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 08, 2021
